Scil Proteins, a German private biotech company specialising in the research, development and production of recombinant proteins, has appointed Ulrich Haupts as its new chief scientific officer. As of 1 October, he will replace Arnd Steuernagel.
Haupts was previously director of protein optimisation at Bayer Healthcare, a position he has held for the last three years. Prior to that, he spent seven years at Direvo Biotech (which was subsequently acquired by Bayer Schering Pharma in 2008) as department head of assay development and later, as vp of r&d biopharmaceuticals.
Dr Haupts also worked for three years at SmithKline Beecham UK in the New Assay Technology group.
Scil Proteins appoints chief scientific officer
Ulrich Haupts joins the biotech firm from Bayer Healthcare
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio